西部制药服务

最新新闻

• Barclays Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $440
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  J.P. Morgan Maintains Visteon(VC.US) With Buy Rating, Raises Target Price to $170
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Citi Initiates West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $412
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• UBS Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $107
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Evercore Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $425
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• Goldman Sachs Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $104
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 公司公告
  4: Visteon | 4: Statement of changes in beneficial ownership of securities-Director Bergman Naomi M.
  SEC · 2026/6/10
• 公司公告
  Visteon | 4: Statement of changes in beneficial ownership of securities-Director Bergman Naomi M.
  SEC · 2025/6/10
• Goldman Sachs Maintains Visteon(VC.US) With Buy Rating, Maintains Target Price $104
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 公司公告
  IGBCR: Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - WAH SEONG (MALAYA) TRADING CO. SDN BHD ("WST")
  Bursa Malaysia · 2025/11/19
• 公司公告
  Visteon | 4: Statement of changes in beneficial ownership of securities-Director Bergman Naomi M.
  SEC · 2024/6/11
• 评级变动
  Goldman Sachs Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $126
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  J.P. Morgan Reaffirms Their Buy Rating on Visteon (VC)
  TipRanks · 2026/10/3
• 评级变动
  Morgan Stanley Maintains West Pharmaceutical Services(WST.US) With Hold Rating, Maintains Target Price $365
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Wolfe Research Downgrades Visteon(VC.US) to Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Morgan Stanley Upgrades West Pharmaceutical Services(WST.US) to Buy Rating, Raises Target Price to $400
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 公司公告
  Visteon | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Wellington Management Group LLP(7.57%),Wellington Group Holdings LLP(7.57%), etc.
  SEC · 2024/11/8
• 评级变动
  J.P. Morgan Maintains Visteon(VC.US) With Buy Rating, Maintains Target Price $145
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• Barclays Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $125
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 评级变动
  J.P. Morgan Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $145
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  A Quick Look at Today's Ratings for West Pharmaceutical Services(WST.US), With a Forecast Between $400 to $410
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Barclays Maintains Visteon(VC.US) With Buy Rating, Maintains Target Price $145
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  RBC Capital Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $129
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Announces Target Price $410
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Analysts Offer Insights on Consumer Cyclical Companies: Reynolds Consumer Products (REYN), Visteon (VC) and Amer Sports, Inc. (AS)
  TipRanks · 2026/7/27

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。